Tissue Regenix to release interim results on September 30

Published 17/09/2025, 07:16
Tissue Regenix to release interim results on September 30

LONDON - Tissue Regenix Group plc (AIM:TRX), a regenerative medical devices company, announced Wednesday it has rescheduled the release of its interim financial results to Tuesday, September 30.

The company had previously communicated its reporting timeline on September 8, according to the statement.

Chief Executive Officer Daniel Lee and Executive Chairman Jay LeCoque will host a live online presentation discussing the interim results via the Investor Meet Company platform at 4pm BST on September 30. The presentation will be accessible to both existing and potential shareholders.

Tissue Regenix specializes in regenerative medicine, utilizing its proprietary decellularisation technology (dCELL®) that removes DNA and cellular material from animal and human soft tissue. This process creates acellular tissue scaffolds that can be used in medical applications without triggering rejection by the patient’s body.

The company’s current product applications focus on sports medicine, foot and ankle injuries, and wound care treatments.

Cavendish Capital Markets Limited serves as the nominated adviser and broker for Tissue Regenix.

This announcement was made through a press release statement issued by the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.